Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
2. More Evidence Shows PrEP Is Highly Effective
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 30 December 2015 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) was again a major HIV story in the mainstream media in 2015, amid growing evidence that it is highly effective both in research studies and in real-world practice when taken consistently.
NHPC 2015: Evidence for PrEP Efficacy Grows, but Implementation Presents Challenges
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 16 December 2015 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) was a major topic at the 2015 National HIV Prevention Conference(NHPC) last week in Atlanta. A growing body of evidence continues to confirm that Truvada PrEP is highly effective for preventing HIV if taken regularly, both in clinical trials and in real-world clinical use. Yet uptake has been uneven, and researchers and front-line health workers are learning about barriers to PrEP implementation and scale-up for diverse population groups.
IPERGAY Pre-exposure Prophylaxis Results Published
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 02 December 2015 00:00
- Written by Gus Cairns
Results from the IPERGAY study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine on December 1, World AIDS Day. The published results are little changed from those presented at the Conference on Retroviruses and Opportunistic Infections last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional comments and are notably cautious about not over-interpreting a study that only had 400 participants -- very small for a prevention study -- and an average of 9 months’ follow-up.
Drug Resistance Acquired During HIV PrEP Rapidly Disappears After Discontinuation
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 15 December 2015 00:00
- Written by Michael Carter
Drug resistance acquired in rare cases of HIV infection occurring while on pre-exposure prophylaxis (PrEP) rapidly disappears once the medication is discontinued, investigators with the Partners PrEP Study Teamreport in the January 2, 2016, edition of AIDS. Use of ultra-sensitive tests performed 6 months after seroconversion and discontinuation of Truvada for PrEP failed to find any remaining resistant virus.
Many More Could Benefit from HIV PrEP, But Not Enough Doctors Are Aware
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Monday, 30 November 2015 00:00
- Written by Liz Highleyman
One-quarter of gay and bisexual men in the U.S. and one-fifth of people who inject drugs, but less than 1% of heterosexual men and women, could benefit from Truvada pre-exposure prophylaxis or PrEP -- more than 1.2 million people in total -- according to a new Centers for Disease Control and Prevention (CDC) Vital Signs report released ahead of World AIDS Day. But a nationwide survey found that one-third of U.S. healthcare providers had not heard about PrEP, prompting the CDC to launch an expanded awareness effort.
More Articles...
- France Approves Truvada for HIV Pre-exposure Prophylaxis
- EACS 2015: Barcelona Clinic Study Counts How Many Gay Men Might Benefit from PrEP
- How Do We Maximize HIV Treatment Access? IAPAC Care Continuum Guidelines Make Recommendations
- Truvada PrEP Appears to Work for Transgender Women, But Only If Used Consistently
Web Design and Development by